Sangeeta Budhia

Sangeeta is the global HTA strategy lead at Parexel, ensuring that our client’s products are positioned for maximum uptake, at optimal price in the shortest possible time. Getting treatments to patients is at the center of what Parexel does. Sangeeta's role is to ensure that global strategies including pivotal clinical trials, long-term data collection studies, real world evidence generation plans and HEOR strategies are prepared for the reimbursement challenges that each product will face. To support this, Sangeeta works closely with global cross-functional teams to ensure alignment on commercial objectives, market access and regulatory strategies and evidence generation plans. Sangeeta also works with market teams/affiliates to ensure alignment with local needs. The key goal is to have the evidence to support the product’s positioning in the local market at minimal risk to the payer.

Work experience

Sangeeta has over 16 years’ experience of working within market access and HEOR, supporting large, small and emerging pharma clients. Supporting the development of their phase III clinical trial program, global market access/evidence generation strategies to local stakeholder mapping and developing reimbursement dossiers/HEOR tool adaptations for Europe and beyond.

Sangeeta has worked on many projects across a variety of market access projects, including early evidence generations strategies, engaging early with European HTA bodies via the early scientific advice process, developing reimbursement ready tools (including, health economic models, comparative effectiveness analyses, real world evidence strategies as well as successful HTA strategies and reimbursement approvals). Sangeeta has worked with both global and country teams to build tailored reimbursement pathways and 'fit for purpose' tools.

Sangeeta works closely with the technical team and is involved in the continual development of Parexel's core service areas and internal processes as well as thought leadership

Education

Sangeeta holds a PhD from the University of Otago, a MSc in Bio-organic Chemistry from the University of Canterbury and a BSc in Chemistry, Genetics and Biochemistry from the University of Canterbury.